Matthias Rath

Prof. Dr. Matthias Rath


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2019 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
MRMatthias Rath
Matthias Rath
APAxel Pagenstecher
Axel Pagenstecher
AHAlexander Hoischen
Alexander Hoischen
UFUte Felbor
Ute Felbor
Background: Cerebral cavernous malformations (CCMs) can cause severe neurological morbidity but our understanding of the mechanisms that drive CCM formation and growth is still incomplete. Recent experimental data suggest that dysfunctional CCM3-deficient endothelial cell clones form cavernous lesions in conjunction with normal endothelial cells. Objective: In this study, we addressed the question whether endothelial cell mosaicism can be found in human cavernous tissue of CCM1 germline mutation carriers. Methods and results: Bringing together single-molecule molecular inversion probes in an ultra-sensitive sequencing approach with immunostaining to visualise the lack of CCM1 protein at single cell resolution, we identified a novel late postzygotic CCM1 loss-of-function variant in the cavernous tissue of a de novo CCM1 germline mutation carrier. The extended unilateral CCM had been located in the right central sulcus causing progressive proximal paresis of the left arm at the age of 15 years. Immunohistochemical analyses revealed that individual caverns are lined by both heterozygous (CCM1+/− ) and compound heterozygous (CCM1−/− ) endothelial cells. Conclusion: We here demonstrate endothelial cell mosaicism within single caverns of human CCM tissue. In line with recent in vitro data on CCM1-deficient endothelial cells, our results provide further evidence for clonal evolution in human CCM1 pathogenesis.

4 June 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
MRMatthias Rath
Matthias Rath
KSKonrad Schwefel
Konrad Schwefel
MMMatteo Malinverno
Matteo Malinverno
DSDariush Skowronek
Dariush Skowronek
ALAlexandra Leopoldi
Alexandra Leopoldi
UFUte Felbor
Ute Felbor
Cerebral cavernous malformations (CCM) are low-flow vascular lesions prone to cause severe hemorrhage-associated neurological complications. Pathogenic germline variants in CCM1, CCM2, or CCM3 can be identified in nearly 100% of CCM patients with a positive family history. In line with the concept that tumor-like mechanisms are involved in CCM formation and growth, we here demonstrate an abnormally increased proliferation rate of CCM3-deficient endothelial cells in co-culture with wild-type cells and in mosaic human iPSC-derived vascular organoids. The observation that NSC59984, an anticancer drug, blocked the abnormal proliferation of mutant endothelial cells further supports this intriguing concept. Fluorescence-activated cell sorting and RNA sequencing revealed that co-culture induces upregulation of proangiogenic chemokine genes in wild-type endothelial cells. Furthermore, genes known to be significantly downregulated in CCM3−/− endothelial cell mono-cultures were upregulated back to normal levels in co-culture with wild-type cells. These results support the hypothesis that wild-type ECs facilitate the formation of a niche that promotes abnormal proliferation of mutant ECs. Thus, targeting the cancer-like features of CCMs is a promising new direction for drug development.

13 December 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
KSKonrad Schwefel
Konrad Schwefel
SSStefanie Spiegler
Stefanie Spiegler
SASabine Ameling
Sabine Ameling
CMChristiane D. Much
Christiane D. Much
RPRobin A. Pilz
Robin A. Pilz
MRMatthias Rath
Matthias Rath
CCM3, originally described as PDCD10, regulates blood‐brain barrier integrity and vascular maturation in vivo. CCM3 loss‐of‐function variants predispose to cerebral cavernous malformations (CCM). Using CRISPR/Cas9 genome editing, we here present a model which mimics complete CCM3 inactivation in cavernous endothelial cells (ECs) of heterozygous mutation carriers. Notably, we established a viral‐ and plasmid‐free crRNA:tracrRNA:Cas9 ribonucleoprotein approach to introduce homozygous or compound heterozygous loss‐of‐function CCM3 variants into human ECs and studied the molecular and functional effects of long‐term CCM3 inactivation. Induction of apoptosis, sprouting, migration, network and spheroid formation were significantly impaired upon prolonged CCM3 deficiency. Real‐time deformability cytometry demonstrated that loss of CCM3 induces profound changes in cell morphology and mechanics: CCM3‐deficient ECs have an increased cell area and elastic modulus. Small RNA profiling disclosed that CCM3 modulates the expression of miRNAs that are associated with endothelial ageing. In conclusion, the use of CRISPR/Cas9 genome editing provides new insight into the consequences of long‐term CCM3 inactivation in human ECs and supports the hypothesis that clonal expansion of CCM3‐deficient dysfunctional ECs contributes to CCM formation.

3 February 2022 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
AGAnna Goc
Anna Goc
ANAleksandra Niedzwiecki
Aleksandra Niedzwiecki
VIVadim Ivanov
Vadim Ivanov
SISvetlana Ivanova
Svetlana Ivanova
MRMatthias Rath
Matthias Rath
Despite vaccine availability, the global spread of COVID-19 continues, largely facilitated by emerging SARS-CoV-2 mutations. Our earlier research documented that a specific combination of plant-derived compounds can inhibit SARS-CoV-2 binding to its ACE2 receptor and controlling key cellular mechanisms of viral infectivity. In this study, we evaluated the efficacy of a defined mixture of plant extracts and micronutrients against original SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants. The composition containing vitamin C, N-acetylcysteine, resveratrol, theaflavin, curcumin, quercetin, naringenin, baicalin, and broccoli extract demonstrated a highest efficacy by inhibiting the receptor-binding domain (RBD) binding of SARS-CoV-2 to its cellular ACE2 receptor by 90%. In vitro exposure of test pseudo-typed variants to this formula for 1 h before or simultaneously administrated to human pulmonary cells resulted in up to 60% inhibition in their cellular entry. Additionally, this composition significantly inhibited other cellular mechanisms of viral infectivity, including the activity of viral RdRp, furin, and cathepsin L. These findings demonstrate the efficacy of natural compounds against SARS-CoV-2 including its mutated forms through pleiotropic mechanisms. Our results imply that simultaneous inhibition of multiple mechanisms of viral infection of host cells could be an effective strategy to prevent SARS-CoV-2 infection.

9 June 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KSKonrad Schwefel
Konrad Schwefel
SSStefanie Spiegler
Stefanie Spiegler
BKBettina C. Kirchmaier
Bettina C. Kirchmaier
PDPatricia K. E. Dellweg
Patricia K. E. Dellweg
CMChristiane D. Much
Christiane D. Much
MRMatthias Rath
Matthias Rath
Loss‐of‐function variants in CCM1/KRIT1 , CCM2 , and CCM3/PDCD10 are associated with autosomal dominant cerebral cavernous malformations (CCMs). CRISPR/Cas9‐mediated CCM3 inactivation in human endothelial cells (ECs) has been shown to induce profound defects in cell‐cell interaction as well as actin cytoskeleton organization. We here show that CCM3 inactivation impairs fibronectin expression and consequently leads to reduced fibers in the extracellular matrix. Despite the complexity and high molecular weight of fibronectin fibrils, our in vitro model allowed us to reveal that fibronectin supplementation restored aberrant spheroid formation as well as altered EC morphology, and suppressed actin stress fiber formation. Yet, fibronectin replacement neither enhanced the stability of tube‐like structures nor inhibited the survival advantage of CCM3 −/− ECs. Importantly, CRISPR/Cas9‐mediated introduction of biallelic loss‐of‐function variants into either CCM1 or CCM2 demonstrated that the impaired production of a functional fibronectin matrix is a common feature of CCM1‐, CCM2‐, and CCM3‐deficient ECs.

17 December 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
MRMatthias Rath
Matthias Rath
SSStefanie Spiegler
Stefanie Spiegler
TSTim M. Strom
Tim M. Strom
JTJohannes Trenkler
Johannes Trenkler
PKPeter Michael Kroisel
Peter Michael Kroisel
UFUte Felbor
Ute Felbor
Grange syndrome is an autosomal recessive condition characterized by arterial occlusions and hypertension. Syndactyly, brachydactyly, bone fragility, heart defects, and learning disabilities have also been reported. Loss‐of‐function variants in YY1AP1 have only recently been associated with Grange syndrome. YY1AP1 encodes for the transcription coactivator yin yang 1‐associated protein 1 which regulates smooth muscle cell proliferation and differentiation. We here report on three siblings with steno‐occlusive arterial disorder and syndactyly in two of them. Whole exome sequencing including near‐splice regions led to the identification of two intronic YY1AP1 variants which were predicted to interfere with normal splicing. Sanger sequencing demonstrated compound‐heterozygosity in all affected siblings. RT‐PCR analyses confirmed skipping of exon 6 on one allele and exonization of 22 bp in intron 6 on the other. This is the first report of biallelic YY1AP1 variants in noncoding regions and just the second family with multiple affected siblings. Therefore, our report further delineates the phenotypic spectrum of Grange syndrome.